| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on June 9, 2004
From the Division of Nephrology (A.K.K., M.S.P.), and Division of Transplant Surgery (G.H., G.M.P.), Medical College of Wisconsin, Milwaukee, and Genzyme Corporation, Boston, Mass (S.L.). * To whom correspondence should be addressed. E-mail: akkhanna{at}mcw.edu.
Background--Long-term treatment of cardiac transplant recipients with cyclosporine results in a progressive decline in kidney function in a large number of patients. This complication is one of the most important prognostic parameters that determine the outcome of cardiac transplantation. Transforming growth factor- Methods and Results--With the use of an experimental rodent model, heterotopic heart transplantation was performed, creating histocompatibility-disparate allografts. Because TGF- Conclusions--These results provide credence to the pivotal role of TGF-
Revised on July 29, 2004
Accepted on August 11, 2004
Anti-Transforming Growth Factor Antibody at Low but Not High Doses Limits Cyclosporine-Mediated Nephrotoxicity Without Altering Rat Cardiac Allograft Survival. Potential of Therapeutic Applications
Ashwani K. Khanna PhD*,
(TGF-
) is one of the most potent mediators of the fibrogenic effects of cyclosporine.
in part mediates both the immunosuppressive and nephrotoxic effects of cyclosporine, recipients were treated with cyclosporine with and without anti-TGF-
antibody to determine whether anti-TGF-
antibody could reduce the nephrotoxic effects of cyclosporine. Intrarenal expression of TGF-
, collagen, fibronectin, matrix metalloproteinase-2, and tissue inhibitor of metalloproteinase-2 was studied with the use of reverse transcription-polymerase chain reaction. Intrarenal expression of TGF-
protein was studied by immunohistochemistry and with the use of ELISA to quantify circulating levels of TGF-
protein in plasma. Cyclosporine-induced graft survival (immunosuppressive effect) was abrogated with a higher concentration (2.5 mg/kg) of anti-TGF-
antibody, whereas a lower concentration (1 mg/kg) inhibited both cyclosporine-induced expression of fibrogenic molecules and renal toxicity.
in immunosuppression-associated renal toxicity in recipients of cardiac transplantation. Furthermore, these findings support a potentially significant therapeutic use of optimal concentration of anti-TGF-
antibody to ameliorate cyclosporine-associated nephrotoxicity in cardiac transplant recipients.
This article has been cited by other articles:
![]() |
A. K. Khanna and G. M. Pieper Reply Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2403 - 2403. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |